Evenity (Romosozumab) Cost in Utah 2026: Pricing, Insurance, and Savings

What Does Evenity (Romosozumab) Actually Cost in Utah?

The average cash-pay price for Evenity at Utah retail pharmacies in 2026 is $1,825 per monthly dose, matching the manufacturer list price set by Amgen and UCB. A complete 12-month treatment course runs approximately $21,900 before any discounts, insurance, or savings programs.

This price applies to the standard 210 mg prefilled syringe formulation administered as two subcutaneous injections (105 mg each) at each monthly visit. Prices across Utah pharmacies show minimal variation because Evenity is a specialty biologic distributed through limited pharmacy networks rather than broadly stocked at every corner drugstore. Specialty pharmacies in Salt Lake City, Provo, and St. George typically price within a few dollars of one another.

The cost difference between Evenity and older osteoporosis therapies is stark. Generic alendronate costs $4 to $15 per month 1. Denosumab (Prolia) runs approximately $1,600 to $1,800 per six-month injection. Teriparatide (Forteo), another anabolic agent, costs approximately $3,500 per month without insurance. Evenity occupies a middle position among bone-building agents, though it remains far more expensive than antiresorptive bisphosphonates.

One factor that makes Evenity's total cost somewhat more predictable than other biologics: the treatment has a hard stop. The FDA-approved label limits use to 12 monthly doses, after which patients transition to an antiresorptive medication like denosumab or a bisphosphonate to maintain bone gains [2]. There is no indefinite refill cycle.

Utah Medicaid Coverage: Currently Not Available

Utah Medicaid does not cover Evenity (romosozumab) for severe osteoporosis as of 2026. This affects approximately 430,000 Medicaid enrollees statewide, including dual-eligible Medicare/Medicaid beneficiaries who might otherwise qualify based on fracture risk.

Patients on Utah Medicaid who need anabolic osteoporosis therapy face limited options. The state formulary generally covers teriparatide (Forteo) and abaloparatide (Tymlos) through prior authorization, though access varies by managed care organization. For patients whose providers believe romosozumab is clinically necessary, a formal exception request can be submitted to the Utah Department of Health and Human Services. These requests require documentation of prior fracture history, T-score results, and failure of or contraindication to at least one antiresorptive agent.

Approval rates for non-formulary biologics through Utah Medicaid exceptions are not publicly reported. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a principal investigator on the FRAME trial, has noted: "Access barriers to anabolic osteoporosis therapies remain one of the most significant obstacles to reducing fracture rates in high-risk populations" 3.

Patients denied coverage should request a written denial letter, which is required to initiate an appeal. Utah Medicaid appeals must be filed within 30 calendar days of the denial notice.

Commercial Insurance Coverage in Utah

Most major commercial insurance plans operating in Utah will cover Evenity with prior authorization. This includes plans from SelectHealth (Intermountain Health's insurer), Blue Cross Blue Shield, UnitedHealthcare, Cigna, Aetna, and Regence BlueCross BlueShield of Utah.

Prior authorization criteria are relatively consistent across carriers. Plans typically require documentation of at least one of the following: a history of osteoporotic fracture, a bone mineral density T-score of −2.5 or below at the hip or lumbar spine, or a high FRAX score indicating elevated 10-year fracture probability 4. Several plans also require evidence that the patient has tried or cannot tolerate a bisphosphonate.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months 4. Insurance medical directors frequently cite this data when evaluating coverage determinations.

SelectHealth, Utah's largest regional insurer, classifies Evenity as a specialty tier medication. Patients on SelectHealth plans can expect copays ranging from $100 to $500 per injection before applying manufacturer savings. High-deductible health plans may require the full $1,825 until the deductible is met.

Medicare Part B covers Evenity as a physician-administered injectable for beneficiaries who meet medical necessity criteria. The standard Part B cost-sharing is 20% after the annual deductible, which translates to roughly $365 per monthly dose. Medicare Supplement (Medigap) plans may cover some or all of that 20% coinsurance.

How the Amgen/UCB Savings Card Works in Utah

The Amgen Assist 360 program offers a copay savings card for Evenity that can reduce out-of-pocket costs to $0 per month for commercially insured patients. The card covers up to $15,000 in copay assistance per calendar year, which is enough to offset nearly all out-of-pocket costs for the 12-dose course.

Eligibility requirements are straightforward. Patients must have commercial (private) insurance that covers Evenity. Government-insured patients, including those on Medicare, Medicaid, TRICARE, or VA benefits, are not eligible for the savings card. Utah residents with commercial coverage can enroll online through the Amgen Assist website or by calling the program directly.

The savings card works at the point of sale. When a specialty pharmacy processes the Evenity prescription, the copay card is applied as a secondary payer, reducing the patient's share. In most cases, the pharmacy handles this automatically after initial enrollment.

For patients without insurance or whose insurance denies coverage, Amgen also operates a separate patient assistance program (PAP) that provides Evenity at no cost to qualifying patients. Income thresholds for the PAP typically fall at or below 300% of the federal poverty level, which for a single person in 2026 is approximately $47,790 annually.

Compounded Romosozumab in Utah: What's Legal

Utah permits compounded romosozumab through licensed 503A compounding pharmacies. This is a legal pathway under both federal law (the Drug Quality and Security Act, section 503A) and Utah state pharmacy regulations 5.

A 503A pharmacy compounds medications based on individual patient prescriptions. The prescribing physician must have a valid patient-prescriber relationship, and the compounded product cannot be a copy of a commercially available drug that is not in shortage, with certain exceptions based on clinical documentation of patient-specific need (such as allergy to an inactive ingredient in the commercial product).

Here is where practical access gets complicated. Romosozumab is a monoclonal antibody, a large-molecule biologic produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. Replicating this molecule in a compounding pharmacy is not the same as compounding a small-molecule drug like testosterone cypionate or a thyroid hormone. The analytical and sterility requirements for biologics are orders of magnitude more demanding.

No Utah 503A pharmacy currently advertises compounded romosozumab at scale. The "$0/month" price point sometimes cited for compounded biologics reflects a theoretical legal pathway, not a practical market reality for this specific molecule. Patients should be cautious of any pharmacy claiming to compound a monoclonal antibody at a fraction of the branded price.

The American Society for Bone and Mineral Research has stated that biosimilar and compounded versions of complex biologics require rigorous analytical and clinical comparability data to ensure safety and efficacy 6.

Telehealth Prescribing in Utah

Utah permits telehealth prescribing of Evenity (romosozumab). A licensed physician or advanced practice clinician can evaluate a patient via video consultation, review DEXA scan results and lab work, and write the prescription without requiring an in-person visit for the initial evaluation.

This is particularly relevant for patients in rural Utah counties. Residents in areas like Garfield, Wayne, or Daggett counties may live 100+ miles from the nearest endocrinologist or rheumatologist with osteoporosis expertise. Telehealth removes the geographic barrier to obtaining the prescription itself.

The actual injection still requires an in-person visit. Evenity is administered as two sequential subcutaneous injections (105 mg each) at each monthly appointment. While the injections can technically be self-administered, most insurance plans and the prescribing information recommend administration by a healthcare professional who can monitor for injection-site reactions and, more critically, for signs of the cardiovascular risk that prompted the FDA's boxed warning 2.

The FDA boxed warning on Evenity states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death 2. The drug should not be prescribed in patients who have had a myocardial infarction or stroke within the preceding year. In the ARCH trial, the rate of adjudicated major adverse cardiac events was 2.5% in the romosozumab group versus 1.9% in the alendronate group over 12 months 4.

Utah-based telehealth platforms that connect patients with osteoporosis specialists include general platforms like Teladoc and MDLive, as well as endocrinology-focused services. HealthRX also offers telehealth consultations with providers experienced in bone-building therapies.

Strategies to Reduce Evenity Cost in Utah

Several concrete approaches can lower the effective price of Evenity for Utah patients.

Step 1: Confirm insurance coverage and tier. Call the number on the back of your insurance card and ask specifically whether romosozumab (Evenity) is on the formulary and what the prior authorization requirements are. Get the prior authorization form number.

Step 2: Apply the Amgen Assist 360 copay card. For commercially insured patients, this single step can reduce copays to $0. Enroll before filling the first prescription.

Step 3: If uninsured or underinsured, apply for Amgen's Patient Assistance Program. The income threshold is generous enough to cover many middle-income patients.

Step 4: Ask about buy-and-bill versus specialty pharmacy. Some Utah rheumatology and endocrinology practices purchase Evenity directly (buy-and-bill) and administer it in-office. This can sometimes yield lower out-of-pocket costs than specialty pharmacy dispensing, depending on the insurance plan's medical benefit versus pharmacy benefit structure.

Step 5: Check for hospital outpatient pricing. University of Utah Health and Intermountain Health both operate outpatient infusion and injection centers. The 340B drug pricing program, available at qualifying facilities, can reduce acquisition costs significantly 7. Patients treated at 340B-eligible facilities may see lower out-of-pocket costs.

Step 6: If Medicare Part B applies, verify coverage through your provider's office. Part B covers physician-administered drugs, and the 20% coinsurance on $1,825 ($365) can be further reduced by Medigap supplemental insurance.

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis recommends that "treatment decisions should account for fracture risk reduction efficacy, potential harms, cost, and patient preferences" 8.

Clinical Value: Is the Cost Justified?

Romosozumab is the only FDA-approved sclerostin inhibitor, a drug class that both builds new bone and reduces bone breakdown simultaneously. No other approved osteoporosis therapy offers this dual mechanism 2.

The FRAME trial (N=7,180) showed that romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% compared to placebo at 12 months (0.5% vs. 1.8%, P<0.001) 9. The ARCH trial showed superiority over alendronate in preventing clinical, nonvertebral, and hip fractures when romosozumab was followed by alendronate 4.

For a postmenopausal woman with a T-score of −3.0 and a prior vertebral fracture, the 10-year hip fracture probability can exceed 10%. A single hip fracture in a Medicare-age patient carries an average first-year cost of $44,000 to $65,000, including surgery, hospitalization, rehabilitation, and long-term care 10. The 12-month Evenity course at $21,900 is less than half the cost of a single hip fracture hospitalization.

Cost-effectiveness analyses have estimated romosozumab followed by alendronate at approximately $50,000 to $75,000 per quality-adjusted life year (QALY) for high-risk patients, which falls below the commonly used $100,000/QALY willingness-to-pay threshold in the United States 10.

Utah-Specific Resources for Osteoporosis Patients

University of Utah Health's Osteoporosis and Metabolic Bone Disease Clinic is the state's primary academic referral center for complex osteoporosis cases. Intermountain Health operates bone health clinics in Salt Lake City, Murray, and Orem. Both systems have specialty pharmacies experienced in processing Evenity prescriptions and prior authorizations.

The Utah Department of Health and Human Services operates the Chronic Disease Prevention Program, which includes bone health screening initiatives in rural counties. While this program does not directly subsidize medication costs, it can connect patients with DEXA screening and provider referrals.

For patients over 65, the State Health Insurance Assistance Program (SHIP) provides free counseling on Medicare coverage options, including help understanding Part B coverage for Evenity and selecting Medigap plans that cover the 20% coinsurance. Utah SHIP can be reached through the Utah Department of Human Services Aging and Adult Services division.

Patients starting Evenity should have a baseline cardiovascular risk assessment, including blood pressure measurement and review of cardiac history, before the first injection. The FDA recommends monitoring for signs of myocardial infarction and stroke throughout the 12-month treatment period 2.